Design and Discovery of Pyridazinone-Based MAT2A Inhibitors Targeting MTAP-Deficient Cance

Yu Zhang published a dataset on figshare in April 2026 detailing the design and optimization of a novel series of pyridazinone-based MAT2A inhibitors. The data likely contains results from structure-activity relationship studies, including IC50 and GI50 values for lead compounds. The dataset is 3.0 KB in size and is available in CSV format.

Use Cases

• Train predictive models for compound potency based on IC50 and GI50 values mentioned in the description.
• Analyze structure-activity relationships for pyridazinone scaffolds described in the study.
• Benchmark pharmacokinetic properties of lead compounds against in vivo efficacy data.
• Identify chemical features correlated with reduced SAM and sDMA levels in MTAP-deficient cell lines.

Strengths

• Includes specific potency metrics for a lead compound (IC50 = 17.5 nM, GI50 = 0.76 μM).
• Data is derived from iterative structure-activity relationship studies and in vivo validation.
• Dataset is openly available under a CC-BY-NC-4.0 license.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (3.0 KB), indicating limited scope.

Provenance

Source

figshare

Collection Method

Likely contains experimental results from medicinal chemistry and pharmacological studies.

Time Range

null

Freshness

Last updated 2026-04-23 17:37:03; freshness should be verified.

Geography

null